nodes	percent_of_prediction	percent_of_DWPC	metapath
Pamidronate—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Pamidronate—Hypersensitivity—Teniposide—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Pamidronate—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Pamidronate—Flushing—Carmustine—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Pamidronate—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Pamidronate—Anaemia—Bleomycin—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Pamidronate—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Pamidronate—Asthenia—Teniposide—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Pamidronate—Malaise—Bleomycin—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Pamidronate—Pruritus—Teniposide—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Pamidronate—Leukopenia—Bleomycin—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Pamidronate—Cardiac disorder—Vincristine—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Pamidronate—Alopecia—Carmustine—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Pamidronate—Body temperature increased—Fludarabine—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Pamidronate—Malnutrition—Carmustine—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Pamidronate—Erythema—Carmustine—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Pamidronate—Cough—Bleomycin—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Pamidronate—Angiopathy—Vincristine—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Pamidronate—Diarrhoea—Teniposide—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Pamidronate—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Pamidronate—Myalgia—Bleomycin—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Pamidronate—Alopecia—Vincristine—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Pamidronate—Back pain—Carmustine—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Pamidronate—Discomfort—Bleomycin—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Pamidronate—Chills—Mitoxantrone—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Pamidronate—Alopecia—Mitoxantrone—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Pamidronate—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Pamidronate—Confusional state—Bleomycin—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Pamidronate—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Pamidronate—Oedema—Bleomycin—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Pamidronate—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Pamidronate—Erythema—Mitoxantrone—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Pamidronate—Infection—Bleomycin—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Pamidronate—Anaemia—Carmustine—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Pamidronate—Back pain—Vincristine—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Pamidronate—Vomiting—Teniposide—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Pamidronate—Agitation—Carmustine—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Pamidronate—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Pamidronate—Asthenia—Fludarabine—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Pamidronate—Rash—Teniposide—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Pamidronate—Dermatitis—Teniposide—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Pamidronate—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Pamidronate—Headache—Teniposide—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Pamidronate—Pruritus—Fludarabine—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Pamidronate—Back pain—Mitoxantrone—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Pamidronate—Leukopenia—Carmustine—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Pamidronate—Anorexia—Bleomycin—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Pamidronate—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Pamidronate—Anaemia—Vincristine—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Pamidronate—Agitation—Vincristine—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Pamidronate—Hypotension—Bleomycin—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Pamidronate—Diarrhoea—Fludarabine—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Pamidronate—Convulsion—Carmustine—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Pamidronate—Hypertension—Carmustine—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Pamidronate—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Pamidronate—Nausea—Teniposide—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Pamidronate—Anaemia—Mitoxantrone—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Pamidronate—Leukopenia—Vincristine—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Pamidronate—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Pamidronate—Myalgia—Carmustine—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Pamidronate—Anxiety—Carmustine—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Pamidronate—Paraesthesia—Bleomycin—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Pamidronate—Malaise—Mitoxantrone—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Pamidronate—Dyspnoea—Bleomycin—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Pamidronate—Renal failure acute—Methotrexate—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Pamidronate—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Pamidronate—Convulsion—Vincristine—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Pamidronate—Hypertension—Vincristine—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Pamidronate—Confusional state—Carmustine—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Pamidronate—Oedema—Carmustine—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Pamidronate—Decreased appetite—Bleomycin—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Pamidronate—Myalgia—Vincristine—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Pamidronate—Cough—Mitoxantrone—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Pamidronate—Infection—Carmustine—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Pamidronate—Vomiting—Fludarabine—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Pamidronate—Convulsion—Mitoxantrone—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Pamidronate—Rash—Fludarabine—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Pamidronate—Dermatitis—Fludarabine—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Pamidronate—Hypertension—Mitoxantrone—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Pamidronate—Pain—Bleomycin—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Pamidronate—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Pamidronate—Headache—Fludarabine—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Pamidronate—Tachycardia—Carmustine—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Pamidronate—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Pamidronate—Myalgia—Mitoxantrone—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Pamidronate—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Pamidronate—Anxiety—Mitoxantrone—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Pamidronate—Lethargy—Methotrexate—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Pamidronate—Discomfort—Mitoxantrone—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Pamidronate—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Pamidronate—Oedema—Vincristine—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Pamidronate—Anorexia—Carmustine—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Pamidronate—Infection—Vincristine—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Pamidronate—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Pamidronate—Osteoarthritis—Methotrexate—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Pamidronate—Confusional state—Mitoxantrone—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Pamidronate—Nervous system disorder—Vincristine—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Pamidronate—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Pamidronate—Hypotension—Carmustine—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Pamidronate—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Pamidronate—Oedema—Mitoxantrone—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Pamidronate—Nausea—Fludarabine—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Pamidronate—Infection—Mitoxantrone—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Pamidronate—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Pamidronate—Shock—Mitoxantrone—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Pamidronate—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Pamidronate—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Pamidronate—Anorexia—Vincristine—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Pamidronate—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Pamidronate—Body temperature increased—Bleomycin—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Pamidronate—Insomnia—Carmustine—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Pamidronate—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Pamidronate—Paraesthesia—Carmustine—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Pamidronate—Hypotension—Vincristine—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Pamidronate—Dyspnoea—Carmustine—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Pamidronate—Somnolence—Carmustine—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Pamidronate—Anorexia—Mitoxantrone—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Pamidronate—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Pamidronate—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Pamidronate—Decreased appetite—Carmustine—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Pamidronate—Hypotension—Mitoxantrone—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Pamidronate—Insomnia—Vincristine—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Pamidronate—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Pamidronate—Paraesthesia—Vincristine—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Pamidronate—Pain—Carmustine—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Pamidronate—Constipation—Carmustine—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Pamidronate—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Pamidronate—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Pamidronate—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Pamidronate—Decreased appetite—Vincristine—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Pamidronate—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Pamidronate—Somnolence—Mitoxantrone—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Pamidronate—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Pamidronate—Feeling abnormal—Carmustine—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Pamidronate—Fatigue—Vincristine—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Pamidronate—Asthenia—Bleomycin—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Pamidronate—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Pamidronate—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Pamidronate—Constipation—Vincristine—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Pamidronate—Pain—Vincristine—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Pamidronate—Pruritus—Bleomycin—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Pamidronate—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Pamidronate—Fatigue—Mitoxantrone—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Pamidronate—Pain—Mitoxantrone—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Pamidronate—Constipation—Mitoxantrone—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Pamidronate—Abdominal pain—Carmustine—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Pamidronate—Body temperature increased—Carmustine—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Pamidronate—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Pamidronate—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Pamidronate—Neutropenia—Methotrexate—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Pamidronate—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Pamidronate—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Pamidronate—Body temperature increased—Vincristine—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Pamidronate—Abdominal pain—Vincristine—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Pamidronate—Hypersensitivity—Carmustine—lymphatic system cancer	0.000983	0.000983	CcSEcCtD
Pamidronate—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000981	0.000981	CcSEcCtD
Pamidronate—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000981	0.000981	CcSEcCtD
Pamidronate—Pneumonia—Methotrexate—lymphatic system cancer	0.000975	0.000975	CcSEcCtD
Pamidronate—Vomiting—Bleomycin—lymphatic system cancer	0.000972	0.000972	CcSEcCtD
Pamidronate—Infestation NOS—Methotrexate—lymphatic system cancer	0.000969	0.000969	CcSEcCtD
Pamidronate—Infestation—Methotrexate—lymphatic system cancer	0.000969	0.000969	CcSEcCtD
Pamidronate—Rash—Bleomycin—lymphatic system cancer	0.000964	0.000964	CcSEcCtD
Pamidronate—Dermatitis—Bleomycin—lymphatic system cancer	0.000963	0.000963	CcSEcCtD
Pamidronate—Asthenia—Carmustine—lymphatic system cancer	0.000958	0.000958	CcSEcCtD
Pamidronate—Renal failure—Methotrexate—lymphatic system cancer	0.000953	0.000953	CcSEcCtD
Pamidronate—Stomatitis—Methotrexate—lymphatic system cancer	0.000945	0.000945	CcSEcCtD
Pamidronate—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000942	0.000942	CcSEcCtD
Pamidronate—Hypersensitivity—Vincristine—lymphatic system cancer	0.000939	0.000939	CcSEcCtD
Pamidronate—Haematuria—Methotrexate—lymphatic system cancer	0.000924	0.000924	CcSEcCtD
Pamidronate—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000914	0.000914	CcSEcCtD
Pamidronate—Asthenia—Vincristine—lymphatic system cancer	0.000914	0.000914	CcSEcCtD
Pamidronate—Diarrhoea—Carmustine—lymphatic system cancer	0.000913	0.000913	CcSEcCtD
Pamidronate—Nausea—Bleomycin—lymphatic system cancer	0.000908	0.000908	CcSEcCtD
Pamidronate—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000905	0.000905	CcSEcCtD
Pamidronate—Asthenia—Mitoxantrone—lymphatic system cancer	0.00089	0.00089	CcSEcCtD
Pamidronate—Dizziness—Carmustine—lymphatic system cancer	0.000883	0.000883	CcSEcCtD
Pamidronate—Haemoglobin—Methotrexate—lymphatic system cancer	0.000875	0.000875	CcSEcCtD
Pamidronate—Diarrhoea—Vincristine—lymphatic system cancer	0.000872	0.000872	CcSEcCtD
Pamidronate—Haemorrhage—Methotrexate—lymphatic system cancer	0.00087	0.00087	CcSEcCtD
Pamidronate—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000859	0.000859	CcSEcCtD
Pamidronate—Urethral disorder—Methotrexate—lymphatic system cancer	0.000853	0.000853	CcSEcCtD
Pamidronate—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000849	0.000849	CcSEcCtD
Pamidronate—Vomiting—Carmustine—lymphatic system cancer	0.000849	0.000849	CcSEcCtD
Pamidronate—Dizziness—Vincristine—lymphatic system cancer	0.000843	0.000843	CcSEcCtD
Pamidronate—Rash—Carmustine—lymphatic system cancer	0.000842	0.000842	CcSEcCtD
Pamidronate—Dermatitis—Carmustine—lymphatic system cancer	0.000841	0.000841	CcSEcCtD
Pamidronate—Headache—Carmustine—lymphatic system cancer	0.000836	0.000836	CcSEcCtD
Pamidronate—Eye disorder—Methotrexate—lymphatic system cancer	0.000813	0.000813	CcSEcCtD
Pamidronate—Vomiting—Vincristine—lymphatic system cancer	0.00081	0.00081	CcSEcCtD
Pamidronate—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000808	0.000808	CcSEcCtD
Pamidronate—Rash—Vincristine—lymphatic system cancer	0.000803	0.000803	CcSEcCtD
Pamidronate—Dermatitis—Vincristine—lymphatic system cancer	0.000803	0.000803	CcSEcCtD
Pamidronate—Headache—Vincristine—lymphatic system cancer	0.000798	0.000798	CcSEcCtD
Pamidronate—Nausea—Carmustine—lymphatic system cancer	0.000793	0.000793	CcSEcCtD
Pamidronate—Angiopathy—Methotrexate—lymphatic system cancer	0.00079	0.00079	CcSEcCtD
Pamidronate—Vomiting—Mitoxantrone—lymphatic system cancer	0.000789	0.000789	CcSEcCtD
Pamidronate—Immune system disorder—Methotrexate—lymphatic system cancer	0.000786	0.000786	CcSEcCtD
Pamidronate—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000784	0.000784	CcSEcCtD
Pamidronate—Rash—Mitoxantrone—lymphatic system cancer	0.000782	0.000782	CcSEcCtD
Pamidronate—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000782	0.000782	CcSEcCtD
Pamidronate—Chills—Methotrexate—lymphatic system cancer	0.000781	0.000781	CcSEcCtD
Pamidronate—Headache—Mitoxantrone—lymphatic system cancer	0.000777	0.000777	CcSEcCtD
Pamidronate—Alopecia—Methotrexate—lymphatic system cancer	0.000769	0.000769	CcSEcCtD
Pamidronate—Malnutrition—Methotrexate—lymphatic system cancer	0.000758	0.000758	CcSEcCtD
Pamidronate—Erythema—Methotrexate—lymphatic system cancer	0.000758	0.000758	CcSEcCtD
Pamidronate—Nausea—Vincristine—lymphatic system cancer	0.000757	0.000757	CcSEcCtD
Pamidronate—Dysgeusia—Methotrexate—lymphatic system cancer	0.000742	0.000742	CcSEcCtD
Pamidronate—Nausea—Mitoxantrone—lymphatic system cancer	0.000737	0.000737	CcSEcCtD
Pamidronate—Back pain—Methotrexate—lymphatic system cancer	0.000733	0.000733	CcSEcCtD
Pamidronate—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000703	0.000703	CcSEcCtD
Pamidronate—Anaemia—Methotrexate—lymphatic system cancer	0.0007	0.0007	CcSEcCtD
Pamidronate—Malaise—Methotrexate—lymphatic system cancer	0.000683	0.000683	CcSEcCtD
Pamidronate—Leukopenia—Methotrexate—lymphatic system cancer	0.000678	0.000678	CcSEcCtD
Pamidronate—Cough—Methotrexate—lymphatic system cancer	0.000661	0.000661	CcSEcCtD
Pamidronate—Convulsion—Methotrexate—lymphatic system cancer	0.000656	0.000656	CcSEcCtD
Pamidronate—Myalgia—Methotrexate—lymphatic system cancer	0.000645	0.000645	CcSEcCtD
Pamidronate—Arthralgia—Methotrexate—lymphatic system cancer	0.000645	0.000645	CcSEcCtD
Pamidronate—Discomfort—Methotrexate—lymphatic system cancer	0.000637	0.000637	CcSEcCtD
Pamidronate—Confusional state—Methotrexate—lymphatic system cancer	0.000623	0.000623	CcSEcCtD
Pamidronate—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000618	0.000618	CcSEcCtD
Pamidronate—Infection—Methotrexate—lymphatic system cancer	0.000614	0.000614	CcSEcCtD
Pamidronate—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000606	0.000606	CcSEcCtD
Pamidronate—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000605	0.000605	CcSEcCtD
Pamidronate—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000598	0.000598	CcSEcCtD
Pamidronate—Anorexia—Methotrexate—lymphatic system cancer	0.000589	0.000589	CcSEcCtD
Pamidronate—Hypotension—Methotrexate—lymphatic system cancer	0.000578	0.000578	CcSEcCtD
Pamidronate—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000563	0.000563	CcSEcCtD
Pamidronate—Insomnia—Methotrexate—lymphatic system cancer	0.000559	0.000559	CcSEcCtD
Pamidronate—Paraesthesia—Methotrexate—lymphatic system cancer	0.000555	0.000555	CcSEcCtD
Pamidronate—Dyspnoea—Methotrexate—lymphatic system cancer	0.000551	0.000551	CcSEcCtD
Pamidronate—Somnolence—Methotrexate—lymphatic system cancer	0.00055	0.00055	CcSEcCtD
Pamidronate—Dyspepsia—Methotrexate—lymphatic system cancer	0.000544	0.000544	CcSEcCtD
Pamidronate—Decreased appetite—Methotrexate—lymphatic system cancer	0.000537	0.000537	CcSEcCtD
Pamidronate—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000534	0.000534	CcSEcCtD
Pamidronate—Fatigue—Methotrexate—lymphatic system cancer	0.000533	0.000533	CcSEcCtD
Pamidronate—Pain—Methotrexate—lymphatic system cancer	0.000529	0.000529	CcSEcCtD
Pamidronate—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00051	0.00051	CcSEcCtD
Pamidronate—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000506	0.000506	CcSEcCtD
Pamidronate—Body temperature increased—Methotrexate—lymphatic system cancer	0.000489	0.000489	CcSEcCtD
Pamidronate—Abdominal pain—Methotrexate—lymphatic system cancer	0.000489	0.000489	CcSEcCtD
Pamidronate—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000456	0.000456	CcSEcCtD
Pamidronate—Asthenia—Methotrexate—lymphatic system cancer	0.000444	0.000444	CcSEcCtD
Pamidronate—Pruritus—Methotrexate—lymphatic system cancer	0.000437	0.000437	CcSEcCtD
Pamidronate—Diarrhoea—Methotrexate—lymphatic system cancer	0.000423	0.000423	CcSEcCtD
Pamidronate—Dizziness—Methotrexate—lymphatic system cancer	0.000409	0.000409	CcSEcCtD
Pamidronate—Vomiting—Methotrexate—lymphatic system cancer	0.000393	0.000393	CcSEcCtD
Pamidronate—Rash—Methotrexate—lymphatic system cancer	0.00039	0.00039	CcSEcCtD
Pamidronate—Dermatitis—Methotrexate—lymphatic system cancer	0.000389	0.000389	CcSEcCtD
Pamidronate—Headache—Methotrexate—lymphatic system cancer	0.000387	0.000387	CcSEcCtD
Pamidronate—Nausea—Methotrexate—lymphatic system cancer	0.000367	0.000367	CcSEcCtD
